SAN FRANCISCO, Oct. 29 – Qiagen on Monday reported a 14 percent drop in operating profits, which it said was a result of the Sept. 11 terrorist attacks on the United States.

The company saw a “significant rebound in sales beginning in early October” and expects continued strong growth in its sector, it said in a statement.

Earnings before interest and tax fell to $10.1 million from $11.8 million recorded in the same period one year ago, and net profit dipped to $6.2 million from $7.2 million, Qiagen said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.